Skip to main content

Table 4 Comparative estimates of costs, QALYs, and ICERs: basecase analysis

From: Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates

  Anti-TNF user Anti-TNF non-user Increment (user vs non-user) 95% CIa
Canada
 Costs 15,741 1703 14,038 (12,179, 15,991)
 QALYs 0.626 0.609 0.017 (−0.008, 0.042)
 ICER    818,186 (330,082, Dominated)
France
 Costs 15,773 1763 14,010 (12,423, 15,694)
 QALYs 0.620 0.607 0.013 (−0.011, 0.036)
 ICER    1,105,859 (375,227, Dominated)
UK
 Costs 16,952 756 16,195 (13,327, 19,181)
 QALYs 0.627 0.606 0.021 (−0.015, 0.059)
 ICER    766,217 (264,164, Dominated)
Germany
 Costs 15,617 1874 13,743 (11,848, 15,759)
 QALYs 0.642 0.617 0.025 (0.001, 0.050)
 ICER    545,808 (272,286, 18,727,278)
Hong Kong 
 Costs 15,764 722 15,042 (11,825, 18,898)
 QALYs 0.619 0.586 0.033 (−0.011, 0.076)
 ICER    456,850 (189,636, Dominated)
  1. aLower bound = 2.5th, upper bound = 97.5th percentile of bootstrapped distribution